Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for Othera Pharmaceuticals, Inc.


Othera Pharmaceuticals, Inc. (www.othera.com) is a privately-held, ophthalmic pharmaceutical company located in Exton, Pennsylvania. Othera is developing proprietary drugs to treat or prevent the three leading causes of blindness and vision impairment in the world - cataracts, age-related macular degeneration Age-related macular degeneration (ARMD)
Degeneration of the macula (the central part of the retina where the rods and cones are most dense) that leads to loss of central vision in people over 60.
 (AMD (Advanced Micro Devices, Inc., Sunnyvale, CA, www.amd.com) A major manufacturer of semiconductor devices including x86-compatible CPUs, embedded processors, flash memories, programmable logic devices and networking chips. ) and glaucoma glaucoma (glôkō`mə), ocular disorder characterized by pressure within the eyeball caused by an excessive amount of aqueous humor (the fluid substance filling the eyeball). . The Company's lead drug, OT-551, is a potent antioxidant antioxidant, substance that prevents or slows the breakdown of another substance by oxygen. Synthetic and natural antioxidants are used to slow the deterioration of gasoline and rubber, and such antioxidants as vitamin C (ascorbic acid), butylated hydroxytoluene  eyedrop formulation to prevent the development of cataracts and AMD. Othera's novel beta-blocker drug, OT-730, is an eyedrop treatment for glaucoma that is designed to provide the same efficacy as current glaucoma therapies, but without the systemic side effects Side effects

Effects of a proposed project on other parts of the firm.
 normally associated with this drug class.
Company:                Othera Pharmaceuticals, Inc.

   Headquarters Address:   730 Springdale Drive
                           Exton, PA 19341

   Main Telephone:         484-897-2800

   Website:                www.othera.com

   Type of Organization:   Private

   Industry:               Health: Pharmaceutical

   Key Executives:         CEO: David Joseph
                           Exec. VP and CSO: William L. Matier, Ph.D.
                           VP Chemistry: Ghanshyam Patil, Ph.D.

   Public Relations
     Contact:              Bill Berry
     Phone:                212-253-8881
     Email:                bberry@berrypr.com
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 22, 2004
Words:155
Previous Article:CUSA, LLC Implements Emergency Response Solution to Ensure Passenger Safety and Provide Increased Fleet Management Efficiency.
Next Article:Research and Markets: French Hospital Register.
Topics:



Related Articles
VALIGEN ACQUIRES BERLIN-BASED INFOGEN AND PHENOTYPE DATABASE.
Othera Pharmaceuticals Closes $13 Million in Venture Capital Financing.
Othera Pharmaceuticals Completes $16 Million Venture Capital Financing.
Othera Pharmaceuticals Announces Results from First Human Phase I Trial For OT-551.
Othera Pharmaceuticals Elects Hans Mueller to Board.
Othera Pharmaceuticals Initiates Phase 2 Clinical Trial for OT-551 in Cataract Prevention; Trial to Address Rapidly-Progressing Form of Cataracts...
Othera Pharmaceuticals to Present at SG Cowen's 26th Annual Health Care Conference.
Othera Pharmaceuticals Appoints Al Reaves as Senior Vice President of Clinical Development.
Othera Pharmaceuticals and the National Eye Institute Commence Dry AMD Study.
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles